Lixisenatide

GLP-1 RAs reduced all-cause death (IRR 0.88, NNT=121), CV death (IRR 0.87, NNT=170), and MACE (IRR 0.87, NNT=66).; Serious adverse events, myocardial infarction, acute kidney failure, heart failure, and infections were reduced by 9-15%.; Gastrointestinal disorders increased by 63% and gallbladder disorders by 26%.; No significant differences were observed for stroke, pancreatitis, or neoplasm.

Select GLP-1 RAs (liraglutide, semaglutide, exenatide) cross the blood-brain barrier in preclinical studies.; CNS penetration of GLP-1 RAs can be proxied by effects on brain connectivity in human participants.; Evidence for reproducible engagement of neural targets related to psychopathology is not fully characterized.

HbA1c reductions ranged from -0.63% (lixisenatide) to -1.79% (tirzepatide 15 mg).; Weight reductions ranged from -0.75 kg to -9.65 kg across agents.; Odds ratios for GI adverse events were similar across compounds despite efficacy differences.; Larger therapeutic efficacy was not systematically linked to higher GI AE or discontinuation rates.

GLP-1 receptor agonists reduce appetite, food intake, and blood sugar spikes by slowing gastric emptying and increasing insulin release.; They exhibit anti-inflammatory, neuroprotective, and neurogenic effects, and can influence dopaminergic signaling in the nucleus accumbens, potentially modifying effects of cocaine, alcohol, and nicotine.; Preliminary investigations indicate therapeutic benefits for dementia, eating disorders, psychopharmacologically induced weight gain, depression, anxiety, and substance use disorders.; Common adverse effects include gastrointestinal issues (nausea, vomiting, diarrhea), while severe side effects may include pancreatitis, allergic reactions, renal dysfunction, and possibly increased thyroid cancer risk.

Semaglutide and lixisenatide had significant reporting odds ratios for ocular AEs (1.25 and 1.96, respectively).; Common ocular AEs included blurred vision, visual impairment, and diabetic retinopathy.; Some ocular AEs occurred as early as 10 days after starting GLP-1 RA treatment.; Gene enrichment analysis suggested potential links between GLP-1-related genes and ocular adverse events.

Semaglutide (ROR 3.34), liraglutide (ROR 2.78), and exenatide (ROR 2.15) were significantly associated with metabolism and nutrition disorders.; Dehydration was the most frequent serious adverse event for liraglutide (23.93%), dulaglutide (20.90%), semaglutide (25.10%), and tirzepatide (32.86%).; Time to onset of adverse events differed significantly between exenatide and other GLP-1 RAs (p < 0.001), with dehydration showing an early failure-type profile for liraglutide, dulaglutide, and semaglutide.

TIR and TBR level 1 showed no significant differences between the two fixed-ratio combinations.; Both groups had significant positive correlations between baseline C-peptide index and TIR at 18 weeks (r=0.679 and r=0.681, P=0.002).; Cut-off C-peptide index values for achieving TIR >70% were 1.258 (sensitivity 77.8%, specificity 100%) for glargine/lixisenatide and 1.099 (sensitivity 57.1%, specificity 90.9%) for degludec/liraglutide.; No significant differences in glycemic variability, therapeutic indices, or BMI were observed between groups.

What is Lixisenatide?

**Mechanism of Action** Lixisenatide is a synthetic, short-acting GLP-1 receptor agonist derived from exendin-4, with a half-life of approximately 3 hours. It binds with high affinity to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon release. Its primary distinguishing feat

How does Lixisenatide work?

Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.

What is the research status of Lixisenatide?

Lixisenatide is currently classified as approved, with 724 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Lixisenatide?

Lixisenatide has a molecular weight of approximately 4858 g/mol (formula C215H347N61O65S).